Lilly's experimental weight-loss drug retatrutide reached one 79-year-old. Other doctors are still waiting for an answer.

Eli Lilly says it will file retatrutide for FDA approval in 2027. Until then, the company controls who gets the experimental obesity drug under compassionate use, and the public record shows one patient: a 79-year-old. At least a handful of other clinicians say they have waited weeks for an answer on compassionate-use access for their own patients, and one only heard back after a reporter called.

STAT's follow-up this week shows that the 79-year-old's special access to retatrutide was not followed by open doors. Other clinicians have been seeking the same access since STAT's earlier report. Two say they have not received answers from Lilly for weeks. A third got a response on Monday; the reply hinted the patient's case might qualify.

Lilly has not publicly said whether the original access was a one-time exception or the start of a broader compassionate-use program. In the gap, clinicians say they have been waiting weeks for a reply, and they are pressing for transparency on whether expanded access is planned, or whether the 79-year-old case stands alone.

For context, retatrutide is a triple agonist: a single molecule that activates three metabolic hormone receptors (GLP-1, GIP, and glucagon). In Phase 3 obesity trials it produced significant improvements in weight and A1C, and Lilly has framed the early data as approaching the weight loss seen with bariatric surgery. The drug is not approved anywhere. The 2027 filing timeline, first reported by CNBC, leaves patients and clinicians outside the company's compassionate-use process until at least next year.

Compassionate use, the FDA pathway that lets a patient receive an unapproved drug when no good alternative exists, is run by the drug's maker. The FDA's role is procedural; the company decides whether to grant access, and it does not publish a list of approved cases. The 79-year-old is the only case on the public record, and the rest of the access queue is undisclosed.

One named patient received retatrutide under compassionate use. Millions of others source GLP-1 family weight-loss drugs on the gray market, a reminder that demand for the category is large and largely unmet by approved supply. Lilly has not said, on the record, why the 79-year-old was chosen, or whether more patients will be added.

The next move is whether Lilly publishes access criteria. If it does not, the access queue stays private.